Jeffrey W. Albers, Director at Blueprint Medicines Corp (BPMC), sold 15,366 shares at $60.13 ($924K) on 2023-11-03, disclosed to the SEC on 2023-11-03.
Scheduled sale ($924k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $60.02 | 3,881 | $233K | 25.2% |
| 2 | $60.02 | 3,881 | $233K | 25.2% |
| 3 | $60.36 | 4,575 | $276K | 29.9% |
| 4 | $61.05 | 59 | $4K | 0.4% |
| 5 | $60.13 | 1,485 | $89K | 9.7% |
| 6 | $60.13 | 1,485 |
| $89K |
| 9.7% |
| Total | $60.15 avg | 15,366 | $924K | 100% |
| Filing → |
| KYMR | SELL | 2025-10-14 | $296K | — | Filing → |
| KYMR | SELL | 2025-06-03 | $311K | — | Filing → |
| BPMC | SELL | 2025-05-29 | $572K | — | Filing → |